InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in ...

Just a few weeks after reporting positive data with izicopan (INF-904) in hidradenitis suppurativa and chronic spontaneous urticaria, Inflarx NV is putting most of its chips on the oral complement C5a ...

Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell therapy, raising the efficacy bar in many forms of the disease. But the ...

A component of the complement system promotes tumor growth by activating myeloid-derived suppressor cells. Figure 1: Multiple pro-inflammatory mediators in the tumor microenvironment increase the ...